Table 5.
Association of HLA-DR3 and DERAA-encoding alleles stratified by the presence of shared epitope alleles with ACPA+ rheumatoid arthritis
| Controls (n = 269) |
ACPA-positive RA patients (n = 143) |
||||
|---|---|---|---|---|---|
| P value | OR (95% CI) | ||||
| SE-positive | DR3-positive | 16 (14.3) | 8 (8.2) | 0.17 | 0.53 (0.22-1.22) |
| DR3-negative | 96 (85.7) | 89 (91.8) | |||
| SE-negative | DR3-positive | 37 (23.6) | 10 (21.7) | 0.84 | 0.90 (0.40-1.98) |
| DR3-negative | 120 (76.4) | 36 (78.3) | |||
| SE-positive | DERAA-positive | 14 (12.5) | 10 (10.3) | 0.85 | 0.58 (0.34-1.90) |
| DERAA-negative | 98 (87.5) | 87 (89.7) | |||
| SE-negative | DERAA-positive | 58 (36.9) | 15 (32.6) | 0.72 | 0.82 (0.41-1.65) |
| DERAA-negative | 99 (63.1) | 31 (67.4) | |||
Percentages relate to total SE-positive or SE-negative controls.
ACPA, anti-citrullinated protein antibody; CI, confidence interval; DERAA, DERAA-encoding allele; DR3, HLA-DR3; OR, odds ratio; RA, rheumatoid arthritis; SE, shared epitope allele.